Beijing Tumor Hospital Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2018
NCT03676946
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Beijing Tumor Hospital

Active Ingredients

Drugs in Phase 2 Trials (1)

zkab001 (1 trial)

Drugs in Phase 1 Trials (1)

gimatecan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Fallopian Tube Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2